Back
Janux Therapeutics, Inc. 10K Form
Sell
30
JANX
Janux Therapeutics, Inc.
Last Price:
$13.59
Seasonality Move:
-11.9%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive JANX News And Ratings
See the #1 stock for the next 7 days that we like better than JANX
JANX Financial Statistics
Sales & Book Value
| Annual Sales: | $10M |
|---|---|
| Cash Flow: | $-28.6M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $15.85 |
| Price / Book: | 0.86 |
Profitability
| EPS (TTM): | -1.83340 |
|---|---|
| Net Income (TTM): | $-113.6M |
| Gross Margin: | $8M |
| Return on Equity: | -11.46% |
| Return on Assets: | -10.98% |
Janux Therapeutics, Inc. Earnings Forecast
Key Janux Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 7 years for JANX is 79.71%.
-
The Selling, General & Administrative Expenses for JANX have been equal to 417.71% of Gross Profit Margin.
-
The Research & Development expenses have been 1,258.96% of Revenue.
-
The Net Earning history of JANX is -1,136.25% of Total Revenues.
-
Per Share Earnings over the last 7 years have been positive in 2 years.
Janux Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | JANX |
| Website: | januxrx.com |
Debt
| Debt-to-Equity Ratio: | 0.02 |
|---|---|
| Current Ratio: | 39.04 |
| Quick Ratio: | 38.67 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
JANX Technical Analysis vs Fundamental Analysis
Sell
30
Janux Therapeutics, Inc. (JANX)
is a Sell
Is Janux Therapeutics, Inc. a Buy or a Sell?
-
Janux Therapeutics, Inc. stock is rated a SellThe current Janux Therapeutics, Inc. [JANX] share price is $14.08. The Score for JANX is 30, which is 40% below its historic median score of 50, and infers higher risk than normal.